ClinicalTrials.gg
CompletedNCT06169319Updated Sep 30, 2025

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

A Phase 2 interventional study of Collagenase Clostridium Histolyticum (CCH) and Placebo in Plantar Fasciitis, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Completed at 39 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Fasciitis, Plantar with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Fasciitis, Plantar · United States.

Enrollment
2nd of 44
231 · median 55
Started
2024
with 2 others
Phase 2
7 of 45
2 open now
Registered
40th of 45
by date

Among the 45 studies in Fasciitis, Plantar with a site in United States, this one is the 2nd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 40th registered.

Fasciitis, Plantar

223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.

Browse Fasciitis, Plantar studies →

Open to participants now

6 of the 45 studies in Fasciitis, Plantar with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Fasciitis, Plantar studies recruiting now, 5 (17%) set no upper age limit and 21 (72%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Fasciitis, Plantar with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

03

Conditions studied

  • Plantar Fasciitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration.
  • Have a diagnosis of plantar fasciitis for ≥6 months, which has not responded to conservative therapies. Conservative therapies may include rest, physical therapy, splinting/bracing, orthotics, icing, physiotherapy, acetaminophen, , or nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Have current foot pain due to plantar fasciitis.

Key Exclusion Criteria:

  • Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain.
  • Has a laboratory abnormality.
  • Has a ≥35 kilograms per meter squared (kg/m\^2).
  • Has a known bleeding disorder, which, in the investigator's opinion, would make the participant unsuitable for enrollment in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Group 1: CCH High Dose

    Participants will receive a high dose of CCH on Day 1.

    Biological: Collagenase Clostridium Histolyticum (CCH)

  • Experimental
    Group 2: CCH Low Dose

    Participants will receive a low dose of CCH on Day 1.

    Biological: Collagenase Clostridium Histolyticum (CCH)

  • Placebo comparator
    Group 3: Placebo

    Participants will receive matching placebo on Day 1.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline at Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change from Baseline up to Day 85 in the Foot Function Index (FFI) Difficulty Subscale Score

    Time frame: Baseline, up to Day 85

  2. Change from Baseline up to Day 85 in the FFI Activity Limitation Subscale Score

    Time frame: Baseline, up to Day 85

  3. Change from Baseline up to Week 12 in the Weekly Mean of the ADP Score as Measured on the Pain Intensity NRS

    Time frame: Baseline, up to Week 12

  4. Change from Baseline up to Day 85 in the FFI Pain Subscale Score

    Time frame: Baseline, up to Day 85

  5. Change from Baseline up to Day 85 in the FFI Total Score

    Time frame: Baseline, up to Day 85

  6. Number of Participants That Used Rescue Analgesic Medication

    Time frame: Up to Day 85

  7. Total Amount (milligrams [mg]) of Rescue Analgesic Medication Used

    Time frame: Up to Day 85

  8. Patient Global Impression of Change (PGIC) Foot Pain Scale Score

    Time frame: Up to Day 85

  9. Clinician Global Impression of Change (CGIC) Scale Score

    Time frame: Up to Day 85

  10. Subject Satisfaction with Treatment Scale Score

    Time frame: Up to Day 85

07

Study locations

39 sites
  • Endo Site 8
    Tucson, Arizona 85712, United States
  • Endo Site 20
    Castro Valley, California 94546, United States
  • Endo Site 13
    Corona, California 92882, United States
  • Endo Site 6
    Encinitas, California 92024, United States
  • Endo Site 11
    Fresno, California 93710, United States
  • Endo Site 16
    Los Angeles, California 90010, United States
  • Endo Site 40
    Los Angeles, California 90063, United States
  • Endo Site 21
    San Francisco, California 94115, United States
  • Endo Site 10
    Tarzana, California 91356, United States
  • Endo Site 37
    Coconut Creek, Florida 33073, United States
  • Endo Clinical Site 3
    Pinellas Park, Florida 33782, United States
  • Endo Site 14
    Sweetwater, Florida 33172, United States
  • Endo Site 7
    Lawrenceville, Georgia 30043, United States
  • Endo Site 23
    Stonecrest, Georgia 30038, United States
  • Endo Site 31
    North Chicago, Illinois 60064, United States
  • Endo Site 28
    O'Fallon, Illinois 62269, United States
  • Endo Site 33
    Overland Park, Kansas 66211, United States
  • Endo Site 35
    Shreveport, Louisiana 71101, United States
  • Endo Clinical Site 2
    Pasadena, Maryland 21122, United States
  • Endo Site 19
    Grand Rapids, Michigan 49525, United States
  • Endo Site 27
    Missoula, Montana 59804, United States
  • Endo Site 38
    Westwood, New Jersey 07675, United States
  • Endo Site 25
    Moore, Oklahoma 73160, United States
  • Endo Site 39
    Portland, Oregon 97202, United States
  • Endo Site 36
    Malvern, Pennsylvania 19355, United States
  • Endo Clinical Site 4
    Bedford, Texas 76021, United States
  • Endo Site 24
    Burleson, Texas 76028, United States
  • Endo Site 17
    Dallas, Texas 75208, United States
  • Endo Site 26
    Dallas, Texas 75235, United States
  • Endo Site 18
    Dallas, Texas 75251, United States
  • Endo Site 30
    Fort Worth, Texas 76104, United States
  • Endo Clinical Site 1
    Georgetown, Texas 78628, United States
  • Endo Site 15
    Houston, Texas 77027, United States
  • Endo Site 9
    McAllen, Texas 78501, United States
  • Endo Site 34
    San Antonio, Texas 78229, United States
  • Endo Site 22
    San Antonio, Texas 78258, United States
  • Endo Clinical Site 5
    Salt Lake City, Utah 84107, United States
  • Endo Site 32
    Newport News, Virginia 23606, United States
  • Endo Site 12
    Suffolk, Virginia 23434, United States
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Sep 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Jan 3, 2024
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Results delay requested
Sep 26, 2025
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169319
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Jan 3, 2024
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Sep 30, 2025

Study contacts

Medical Director
study director · Endo USA Inc., a Keenova Therapeutics Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion